Skip to Main Content

Paper Details

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
J Clin Oncol
296
2015
/, BRCA, BRCA1/2, BRCA1/2 mutation, BRCA1/2 mutations, HRD, Metastatic Triple-Negative Breast Cancer, PAM50, PAM50 gene, PATIENTS, PIK3CA, PIK3CA mutation, Patients, Platinum, TBCRC009, carboplatin, cisplatin, homologous recombination deficiency, mTNBC, metastatic triple-negative breast cancer, p53, p63, p73, patients, platinum, tumors
Author NameAffiliation
Steven J IsakoffMassachusetts General Hospital Cancer Center Steven J. Isakoff, Harvard Medical School Erica L. Mayer, Dana-Farber Cancer Institute Steven E. Come, Beth Israel Deaconess Medical Center, Massachusetts General Hospital/North Shore Cancer Center, Memorial Sloan Kettering Cancer Center, The University of North Carolina at Chapel Hill, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center
Lisa A CareyMassachusetts General Hospital Cancer Center Steven J. Isakoff, Harvard Medical School Erica L. Mayer, Dana-Farber Cancer Institute Steven E. Come, Beth Israel Deaconess Medical Center, Massachusetts General Hospital/North Shore Cancer Center, Memorial Sloan Kettering Cancer Center, The University of North Carolina at Chapel Hill, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center
Minetta C LiuMassachusetts General Hospital Cancer Center Steven J. Isakoff, Harvard Medical School Erica L. Mayer, Dana-Farber Cancer Institute Steven E. Come, Beth Israel Deaconess Medical Center, Massachusetts General Hospital/North Shore Cancer Center, Memorial Sloan Kettering Cancer Center, The University of North Carolina at Chapel Hill, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center
Vered StearnsMassachusetts General Hospital Cancer Center Steven J. Isakoff, Harvard Medical School Erica L. Mayer, Dana-Farber Cancer Institute Steven E. Come, Beth Israel Deaconess Medical Center, Massachusetts General Hospital/North Shore Cancer Center, Memorial Sloan Kettering Cancer Center, The University of North Carolina at Chapel Hill, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center
Dianne M FinkelsteinMassachusetts General Hospital Cancer Center Steven J. Isakoff, Harvard Medical School Erica L. Mayer, Dana-Farber Cancer Institute Steven E. Come, Beth Israel Deaconess Medical Center, Massachusetts General Hospital/North Shore Cancer Center, Memorial Sloan Kettering Cancer Center, The University of North Carolina at Chapel Hill, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center
Judy E GarberMassachusetts General Hospital Cancer Center Steven J. Isakoff, Harvard Medical School Erica L. Mayer, Dana-Farber Cancer Institute Steven E. Come, Beth Israel Deaconess Medical Center, Massachusetts General Hospital/North Shore Cancer Center, Memorial Sloan Kettering Cancer Center, The University of North Carolina at Chapel Hill, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center
Eric P WinerMassachusetts General Hospital Cancer Center Steven J. Isakoff, Harvard Medical School Erica L. Mayer, Dana-Farber Cancer Institute Steven E. Come, Beth Israel Deaconess Medical Center, Massachusetts General Hospital/North Shore Cancer Center, Memorial Sloan Kettering Cancer Center, The University of North Carolina at Chapel Hill, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center
  • 1 - 7

Datasets